VMD-928

VMD-928 is an orally active, allosteric, irreversible and selective tropomyosin receptor kinase A (TrkA) inhibitor. VMD-928 blocks the downstream signaling pathways triggered by the binding of nerve growth factor (NGF) to TrkA, thereby inhibiting cell proliferation, invasion, and promoting cancer cell death. VMD-928 is promising for research of various cancers, including prostate cancer, thymic carcinoma, mesothelioma, squamous cell carcinoma of the head and neck, squamous cell carcinoma of the lung, ovarian cancer, hepatocellular carcinoma[1][2].

Product Specifications

CAS Number

[1802770-18-8]

UNSPSC

12352005

Target

Trk Receptor

Related Pathways

Neuronal Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

O=C(C1=CC=C(NC(C=C(N2CCN(C3CCCCC3)CC2)C(N)=C4C(C5=C6C=CC=C5)=O)=C4C6=O)C=C1)O

Molecular Formula

C31H32N4O4

Molecular Weight

524.61

References & Citations

[1]Di Donato M, et al. The nerve growth factor-delivered signals in prostate cancer and its associated microenvironment: when the dialogue replaces the monologue. Cell Biosci. 2023 Mar 20;13 (1) :60.|[2]Chung V, et al. First-time in-human study of VMD-928, an allosteric and irreversible TrkA selective inhibitor, in patients with solid tumors or lymphoma[J]. 2019.